Protalix BioTherapeutics’ taliglucerase alfa because Gaucher blight granted French ATU
Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that the French regulatory specialist has granted an Autorisation Temporaire d’Utilisation (ATU), or Makeshift Authorization benefit of Smoke, suited for taliglucerase alfa into the treatment of Gaucher condition. An ATU is the regulatory system familiar close the French Fettle Products and Cover Activity to reach non-approved drugs ready to patients in France when a true celebrated fitness demand exists. This ATU allows patients with Gaucher blight in France to ascertain treatment with taliglucerase alfa ahead marketing authorization in place of the spin-off is granted in the European Junction. Payment in place of taliglucerase alfa has been secured utterly administration allocations to hospitals.
"We are happy to be capable to offer taliglucerase alfa to Gaucher patients in France inferior to the ATU program," said Dr. David Aviezer, President and Chief Superintendent Officer of the law of the Actors.
OUTSET Protalix BioTherapeutics, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
